LOADING
We have always believed that the clinical trials industry has great potential in the Republic of Kazakhstan, and therefore we opened our representative office in this country back in 2007.
We actively participate in the development of the clinical trials industry in the Republic of Kazakhstan: we share our expertise with industry colleagues, cooperate with regulators and pharmaceutical companies, and take part in organizing trainings and conferences.
Kazakhstan offers a cost-effective alternative for clients who plan to conduct clinical trials in Russia and the EAEU and CIS countries and prefer to minimize possible political risks in advance.
On February 12, 2016, the Agreement on Common Principles and Rules for the Circulation of Medicines and Medical Devices within the Eurasian Economic Union entered into force in Russia, the Republic of Kazakhstan, Armenia, Belarus and Kyrgyzstan (member countries of the Eurasian Economic Union, EAEU). In accordance with this Agreement it became possible to conduct clinical trials of a medicine / medical device in one of these EAEU member states, and later apply for a marketing authorization in other EAEU countries under a simplified procedure.
Thanks for all your hard work on the project and for making the TRD study a success in Kazakhstan. I hope that we can get another study for Kazakhstan in the near future so that we can work together again.
We are able to work with clients around the world, both from Western countries and from the Asia-Pacific region.
We are able to work both as the only contract research organization selected by the Sponsor to conduct a clinical trial, and as part of an international multicenter project team, interacting with other contract research organizations and service providers. 90 out of 344 clinical studies conducted by Synergy are international multicenter studies.
We offer foreign clients access to the Russian pharmaceutical market to obtain a marketing authorization for their developed products in the Russian Federation.
We also offer access to an extensive database of treatment-naive patients and a well-organized infrastructure for conducting clinical trials of medicines and medical devices in the Russian Federation, along with high quality of the obtained statistical data and the possibility of preparing these data in native formats for foreign regulators.
I would like to thank all of you for very good preparation to the co-monitoring visits. I was really impressed with very good quality of data that was shown in each of the sites.